European Registry of Next Generation Imaging in Advanced Prostate Cancer
RING
1 other identifier
observational
600
8 countries
24
Brief Summary
The RING study is a European registry collecting real-world data on advanced prostate cancer (APC) imaging. It aims to evaluate the role of next-generation imaging (NGI), such as PET/CT and whole-body MRI, in detecting and monitoring the disease compared to conventional imaging. Men aged 18 or older with histologically confirmed prostate cancer are eligible to participate in the study if they require imaging to assess potential metastases, either at diagnosis or after relapse and sign a consent form. Patients will receive standard care with no experimental treatments. Imaging and treatment decisions will follow routine clinical practice. Data will be collected from medical records and analysed for research. This study will help doctors understand when NGI should be used, how it affects treatment decisions, and its impact on patient outcomes.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Sep 2024
Typical duration for all trials
24 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 17, 2024
CompletedFirst Submitted
Initial submission to the registry
February 26, 2025
CompletedFirst Posted
Study publicly available on registry
March 10, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 23, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
December 23, 2026
ExpectedMarch 11, 2025
March 1, 2025
1.3 years
February 26, 2025
March 8, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Proportion of patients requiring NGI, conventional imaging, or a combination of both imaging tools.
Number of patients who require NGI, conventional imaging, or a combination of both imaging tools with the respect to local protocols
4 - 6 weeks
Proportion of patients with a change of treatment determined by the imaging test result, when multiple imaging tests have been realized
Number of patients who received multiple imaging tests for whom the result of the particular imaging test has lead to the change in management
4-6 weeks
Other Outcomes (1)
Clinical variables associated to NGI or conventional imaging
4-6 weeks
Study Arms (3)
New generation imaging
Patients with prostate cancer at high risk for harbouring metastatic deposits at the hormone-sensitive stage, who require imaging exploration either at the diagnostic workup of a "naïve" patient or at biochemical relapse/progression after local treatment with the use of next generation imaging ( whole-body MRI and PET/CT with new tracers (F/Ga-PSMA, 18F-fluciclovine)
Conventional imaging
Patients with prostate cancer at high risk for harbouring metastatic deposits at the hormone-sensitive stage, who require imaging exploration either at the diagnostic workup of a "naïve" patient or at biochemical relapse/progression after local treatment with the use of conventional imaging ( CT and bone scan)
Conventional imaging and New generation imaging
Patients with prostate cancer at high risk for harbouring metastatic deposits at the hormone-sensitive stage, who require imaging exploration either at the diagnostic workup of a "naïve" patient or at biochemical relapse/progression after local treatment with the use of conventional imaging ( CT and bone scan) AND next generation imaging
Interventions
Imaging will be done according to local protocols and/or guidelines of EAU
Eligibility Criteria
Outpatient "naive" or relapsed/progressed patients above 18 years with prostate cancer at high risk for harbouring metastatic deposits at the hormone-sensitive stage, who require imaging exploration (conventional, NGI, or their combination)
You may qualify if:
- Adult male patients (≥18 years with no upper age limit).
- Histologically proven prostate cancer.
- Patients who require imaging exploration (conventional, Next-Generation Imaging (NGI), or their combination) at high risk for harbouring metastatic deposits at the hormone-sensitive stage, either at the diagnostic workout of a "naïve" patient or at biochemical relapse/progression after local treatment.
- Patients who authorize their participation in the study by signing a written informed consent form (ICF).
You may not qualify if:
- Patients participating in other interventional or non-interventional study which requires NGI as a triage test for metastatic assessment.
- Patients with evidence of any other clinically significant disease or condition which in the opinion of the investigator discourages their participation in the study.
- Patients who will not be able to complete the study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Fundacio Puigvertlead
- European Association of Urology Research Foundationcollaborator
- GUARD Consortium (Genitourinary Alliance for Research and Development)collaborator
- European Association of Urology - Section of Urological Imagingcollaborator
- Johnson & Johnsoncollaborator
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Paucollaborator
Study Sites (24)
Universitair Ziekenhuis Leuven
Leuven, Belgium
Hospital Center University De Lille
Lille, France
Hospices Civils de Lyon
Lyon, France
University Hospitals Pitié Salpêtrière
Paris, France
Bonn University Hospital
Bonn, Germany
Martini Klinik
Hamburg, Germany
München LMU L MU-University Clinic
Munich, Germany
Urologische Klinik München - Planegg
Planegg, Germany
Universitätsklinik Tübingen
Tübingen, Germany
IRCCS Universit of Bologna
Bologna, Italy
Azienda Ospedaliero-Universitaria Careggi
Florence, Italy
Azienda Ospedaliero-Universitaria Careggi
Florence, Italy
IRCCS Ospedale San Raffaele
Milan, Italy
ERASMUS MC & Franciscus Hospital
Rotterdam, Netherlands
Uniwersytet Jagielloński Collegium Medicum
Krakow, Poland
Fundació Puigvert
Barcelona, Spain
Hospital de la Santa Creu i Sant Pau
Barcelona, Spain
Hospital Universitario Reina Sofia
Córdoba, Spain
Hospital Universitario La Paz
Madrid, Spain
Hospital Universitario Ramón y Cajal
Madrid, Spain
Hospital Universitario de Canarias
San Cristóbal de La Laguna, Spain
Hospital Universitario Marqués de Valdecilla
Santander, Spain
Hospital Clínico Universitario de Santiago
Santiago de Compostela, Spain
Skånes universitetssjukhus Malmö
Malmo, Sweden
Related Publications (1)
Chernysheva D, Fanti S, Bjartell A, Afferi L, Breda A, Palou J, Padhani AR, Sanguedolce F. European Registry of Next Generation Imaging in Advanced Prostate Cancer (RING): protocol for an international, prospective registry study. BMJ Open. 2025 Dec 3;15(12):e106022. doi: 10.1136/bmjopen-2025-106022.
PMID: 41338644DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Francesco Sanguedolce, MD, PhD
Fundació Puigvert
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 24 Months
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Chief Investigator
Study Record Dates
First Submitted
February 26, 2025
First Posted
March 10, 2025
Study Start
September 17, 2024
Primary Completion
December 23, 2025
Study Completion (Estimated)
December 23, 2026
Last Updated
March 11, 2025
Record last verified: 2025-03
Data Sharing
- IPD Sharing
- Will not share
GDPR regulations